Skip to content

Released Mar 22, 2023, after the close

10-K filed Mar 22, 2023, 81 days after period end · 0000950170-23-009184

Q4 2022 · 10-K

derived · Computed from the longer spans the company filed.

Revenue—
Net Income-$22.40MderivedN/M vs Q4 2021N/M vs Q3 2022
EPS, diluted—Not derived. Share counts vary by quarter.
Operating Incomederived-$22,978,000N/M
Operating Cash Flowderived-$19,254,000N/M
Free Cash Flowderived-$19,254,000N/M

What the release said

The release

Same quarter

MetricQ4 2022derived from reported figuresQ4 2021derived from reported figuresQ4 2020Q4 2019
Revenue——$1.04M$4.77M
Net Income-$22.40M-$60.26M-$39.42M-$27.08M
EPS Diluted——-$1.11-$0.99

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Assembly Biosciences, Inc. · CIK 1426800 · Engraved from SEC EDGAR